ERBB2 and vascular disorder: In an analysis of anti-HER2 therapy from the Italian pharmacovigilance database, cardiac failure, vascular disorder and infusion-related reactions with hypersensitivity were more frequent in the treatment of pertuzumab and trastuzumab [20].